US36870H1032 - Common Stock
GENELUX CORP
NASDAQ:GNLX (5/9/2024, 9:47:57 AM)
3.705
-0.08 (-2.24%)
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 15 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The firm is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA
P: 18052679889
Employees: 15
Website: https://genelux.com/
GNLX stock results show that Genelux missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genelux (NASDAQ:GNLX) just reported results for the fourth quarter of 2023.Gene...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update...
Here you can normally see the latest stock twits on GNLX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: